Stock Analysis
- United Kingdom
- /
- Medical Equipment
- /
- AIM:POLX
Polarean Imaging Full Year 2023 Earnings: US$0.055 loss per share (vs US$0.066 loss in FY 2022)
Polarean Imaging (LON:POLX) Full Year 2023 Results
Key Financial Results
- Revenue: US$890.9k (down 14% from FY 2022).
- Net loss: US$11.9m (loss narrowed by 14% from FY 2022).
- US$0.055 loss per share (improved from US$0.066 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Polarean Imaging shares are down 8.3% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for Polarean Imaging (4 are a bit concerning!) that you need to be mindful of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About AIM:POLX
Polarean Imaging
Operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States.